Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder

By LabMedica International staff writers
Posted on 28 Mar 2025

Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or blood cancer. More...

Although the exact cause of CCUS remains unclear, studies have shown that it can often progress into blood cancer. Patients with CCUS are at a tenfold increased risk of developing conditions such as myelodysplastic syndromes or acute myeloid leukemia. Now, researchers have developed a new method to predict the likelihood of cancer development in individuals with CCUS.

An international team of researchers led by Northwestern University (Evanston, IL, USA) conducted a study involving over 350 patients with CCUS. By analyzing the genetic mutations, low blood counts, and corresponding outcomes, the scientists created a scoring system aimed at better risk stratification and predicting the potential for blood cancer development. The team then validated their model with a separate group of 100 CCUS patients, finding that it accurately predicted the risk of blood cancer. The results, published in the journal Blood, demonstrate that this risk scoring system can help identify which patients are most likely to develop cancer, potentially allowing for early intervention in the future. Going forward, the researchers plan to integrate this scoring system into future clinical trials for CCUS patients.

“The take-home message from this is that there are three major predictors of outcomes in these patients,” said Yasmin Abaza, MD, assistant professor of Medicine in the Division of Hematology and Oncology, who was a co-author of the study. “If you have particular mutations, we call them splicing factor mutations, which are one of the major weights in determining prognosis. Also, if you have a platelet count of less than 100. The third is having two or more genetic mutations.”

“This scoring system has not been adopted yet, but hopefully as we have more patients and further validate and compare it to other scoring systems, later on it could be implemented clinically,” Abaza added.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.